DK3322701T3 - Ethynylderivater som metabotropiske glutamatreceptormodulatorer - Google Patents
Ethynylderivater som metabotropiske glutamatreceptormodulatorer Download PDFInfo
- Publication number
- DK3322701T3 DK3322701T3 DK16739442.8T DK16739442T DK3322701T3 DK 3322701 T3 DK3322701 T3 DK 3322701T3 DK 16739442 T DK16739442 T DK 16739442T DK 3322701 T3 DK3322701 T3 DK 3322701T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor modulators
- glutamate receptor
- metabotropic glutamate
- ethynyl derivatives
- ethynyl
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176854 | 2015-07-15 | ||
| PCT/EP2016/066393 WO2017009275A1 (en) | 2015-07-15 | 2016-07-11 | Ethynyl derivatives as metabotropic glutamate receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3322701T3 true DK3322701T3 (da) | 2019-07-08 |
Family
ID=53758003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16739442.8T DK3322701T3 (da) | 2015-07-15 | 2016-07-11 | Ethynylderivater som metabotropiske glutamatreceptormodulatorer |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10189848B2 (da) |
| EP (1) | EP3322701B1 (da) |
| JP (1) | JP6761821B2 (da) |
| KR (1) | KR20180026438A (da) |
| CN (1) | CN107580598B (da) |
| AR (1) | AR105341A1 (da) |
| AU (1) | AU2016292863B2 (da) |
| CA (1) | CA2984711C (da) |
| CL (1) | CL2018000036A1 (da) |
| CO (1) | CO2017011174A2 (da) |
| CR (1) | CR20180022A (da) |
| DK (1) | DK3322701T3 (da) |
| ES (1) | ES2733468T3 (da) |
| HR (1) | HRP20191139T1 (da) |
| HU (1) | HUE045145T2 (da) |
| IL (1) | IL255096B (da) |
| LT (1) | LT3322701T (da) |
| MA (1) | MA42442B1 (da) |
| MX (1) | MX374409B (da) |
| PE (1) | PE20180356A1 (da) |
| PH (1) | PH12018500106A1 (da) |
| PL (1) | PL3322701T3 (da) |
| PT (1) | PT3322701T (da) |
| RS (1) | RS58929B1 (da) |
| RU (1) | RU2721776C9 (da) |
| SI (1) | SI3322701T1 (da) |
| TR (1) | TR201909160T4 (da) |
| TW (1) | TWI612962B (da) |
| UA (1) | UA120463C2 (da) |
| WO (1) | WO2017009275A1 (da) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| TR201909160T4 (tr) | 2015-07-15 | 2019-07-22 | Hoffmann La Roche | Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri. |
| JP6936305B2 (ja) * | 2016-07-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | エチニル誘導体 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| JP7633676B2 (ja) | 2018-07-26 | 2025-02-20 | ドメイン・セラピューティクス | 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2024196599A2 (en) * | 2023-03-10 | 2024-09-26 | Brightseed, Inc. | Compositions and methods for modulating stress and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| ZA200709819B (en) * | 2005-05-24 | 2009-09-30 | Serono Lab | Tricyclic spiro derivatives as CRTH2 modulators |
| JP2010502617A (ja) | 2006-08-31 | 2010-01-28 | シェーリング コーポレイション | 抗菌物質として有用なヒダントイン誘導体 |
| WO2008151184A1 (en) | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| CA2712605C (en) | 2008-02-01 | 2017-02-07 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
| US8513381B2 (en) | 2009-01-19 | 2013-08-20 | Fondazione Irccs Ca' Granda-Ospedale Maggiore Policlinico | Melanocortin analogs with antimicrobial activity |
| US9097713B2 (en) | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
| US8779157B2 (en) | 2009-09-04 | 2014-07-15 | Vanderbilt University | MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| PH12013501895A1 (en) | 2011-04-26 | 2013-10-14 | Hoffmann La Roche | Ethynyl derivatives as positive allosteric modulators of the mglur5 |
| MY165141A (en) | 2011-04-26 | 2018-02-28 | Hoffmann La Roche | Pyrazolidin-3-one derivatives |
| CA2837312A1 (en) | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| UA110995C2 (uk) | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| EP2875000B1 (en) | 2012-07-17 | 2016-09-21 | F. Hoffmann-La Roche AG | Arylethynyl derivatives |
| EP2909178B1 (en) | 2012-10-18 | 2016-10-05 | F. Hoffmann-La Roche AG | Ethynyl derivatives as modulators of mglur5 receptor activity |
| CN104718191B (zh) | 2012-10-18 | 2016-06-29 | 霍夫曼-拉罗奇有限公司 | 作为mglur5受体活性调节剂的乙炔基衍生物 |
| CN105121424B (zh) | 2013-02-18 | 2019-01-22 | 华领医药技术（上海）有限公司 | mGluR调节剂 |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| WO2015044075A1 (en) * | 2013-09-25 | 2015-04-02 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| TWI649310B (zh) | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| AU2015221388A1 (en) | 2014-02-19 | 2016-08-04 | Emergent Biosolutions Canada Inc. | Methods of modulating an immune response |
| BR112016017816A8 (pt) | 2014-02-25 | 2020-06-30 | Hoffmann La Roche | derivados de etinila, seus usos, e composição farmacêutica |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CA2963470A1 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| WO2016146600A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4 |
| TR201909160T4 (tr) | 2015-07-15 | 2019-07-22 | Hoffmann La Roche | Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri. |
| JP6936305B2 (ja) | 2016-07-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | エチニル誘導体 |
-
2016
- 2016-07-11 TR TR2019/09160T patent/TR201909160T4/tr unknown
- 2016-07-11 AU AU2016292863A patent/AU2016292863B2/en active Active
- 2016-07-11 CN CN201680026777.2A patent/CN107580598B/zh active Active
- 2016-07-11 PT PT16739442T patent/PT3322701T/pt unknown
- 2016-07-11 JP JP2017564709A patent/JP6761821B2/ja active Active
- 2016-07-11 RS RS20190819A patent/RS58929B1/sr unknown
- 2016-07-11 PE PE2017002337A patent/PE20180356A1/es unknown
- 2016-07-11 CR CR20180022A patent/CR20180022A/es unknown
- 2016-07-11 PL PL16739442T patent/PL3322701T3/pl unknown
- 2016-07-11 HU HUE16739442A patent/HUE045145T2/hu unknown
- 2016-07-11 WO PCT/EP2016/066393 patent/WO2017009275A1/en not_active Ceased
- 2016-07-11 ES ES16739442T patent/ES2733468T3/es active Active
- 2016-07-11 RU RU2018103944A patent/RU2721776C9/ru active
- 2016-07-11 SI SI201630292T patent/SI3322701T1/sl unknown
- 2016-07-11 UA UAA201801133A patent/UA120463C2/uk unknown
- 2016-07-11 HR HRP20191139TT patent/HRP20191139T1/hr unknown
- 2016-07-11 EP EP16739442.8A patent/EP3322701B1/en active Active
- 2016-07-11 DK DK16739442.8T patent/DK3322701T3/da active
- 2016-07-11 LT LTEP16739442.8T patent/LT3322701T/lt unknown
- 2016-07-11 MX MX2018000592A patent/MX374409B/es active IP Right Grant
- 2016-07-11 MA MA42442A patent/MA42442B1/fr unknown
- 2016-07-11 KR KR1020187000004A patent/KR20180026438A/ko active Pending
- 2016-07-11 CA CA2984711A patent/CA2984711C/en active Active
- 2016-07-13 AR ARP160102117A patent/AR105341A1/es unknown
- 2016-07-14 TW TW105122266A patent/TWI612962B/zh active
-
2017
- 2017-10-17 IL IL255096A patent/IL255096B/en active IP Right Grant
- 2017-10-30 CO CONC2017/0011174A patent/CO2017011174A2/es unknown
-
2018
- 2018-01-05 CL CL2018000036A patent/CL2018000036A1/es unknown
- 2018-01-12 US US15/869,268 patent/US10189848B2/en active Active
- 2018-01-12 PH PH12018500106A patent/PH12018500106A1/en unknown
- 2018-12-14 US US16/220,512 patent/US11034699B2/en active Active
-
2021
- 2021-05-09 US US17/315,349 patent/US12006323B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3322701T3 (da) | Ethynylderivater som metabotropiske glutamatreceptormodulatorer | |
| DK3625228T3 (da) | Pyrimidinderivater som pge2-receptormodulatorer | |
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| DK3928836T3 (da) | N-substituerede indolderivater som pge2-receptormodulatorer | |
| DK3094631T4 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
| DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
| DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
| DK3131902T3 (da) | Forbindelser som ROR-gamma-modulatorer | |
| DK3363790T3 (da) | 1,2,4-oxadiazolderivater som immunmodulatorer | |
| DK3539961T3 (da) | Polycykliske amidderivativer som cdk9-inhibitorer | |
| DK3288940T3 (da) | Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer | |
| DK3319963T3 (da) | Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer | |
| DK3625222T3 (da) | Phenylderivater som pge2-receptormodulatorer | |
| DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
| DK3265459T3 (da) | Amidforbindelser som 5-ht4-receptoragonister | |
| DK3022174T3 (da) | Derivater af n-urinstof-substituerede aminosyrer som formylpeptidreceptormodulatorer | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| EP3374386C0 (en) | PROTEASE-ACTIVATED RECEPTOR TYPE 2 MODULATORS | |
| DK3347349T3 (da) | Fluorindolderivater som muskarin m1-receptor-positive allosteriske modulatorer | |
| DK3661941T3 (da) | Thiazolopyridinderivater som adenosinreceptor-antagonister | |
| DK4056557T3 (da) | Benzazepinderivater nyttige som medikamenter | |
| IL242682B (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| IL263884A (en) | Ethynyl derivatives | |
| DK3345899T3 (da) | Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer | |
| DK3303316T3 (da) | Ethynylderivater |